Having trouble accessing articles? Reset your cache.

Crossover investors help Arcutis raise $95M to advance PDE-4 inhibitor for psoriasis

Arcutis raised $94.5 million in a series C financing to advance lead product ARQ-151, a topical formulation of the PDE-4 inhibitor roflumilast, through Phase III trials for mild-to-moderate psoriasis.

Arcutis Biotherapeutics Inc. co-founder Chairman Bhaskar Chaudhuri

Read the full 356 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE